抗体片段市场规模、份额和成长分析（按特异性、片段类型、应用、最终用途和地区划分）－2026-2033年产业预测

预计到 2024 年，全球抗体片段市场规模将达到 76.2 亿美元，到 2025 年将达到 80.6 亿美元，到 2033 年将达到 126.5 亿美元，预测期（2026-2033 年）的复合年增长率为 5.8%。

在对精准、灵活、高效的治疗和诊断试剂日益增长的需求推动下，抗体片段市场正崛起为生物製药行业的关键组成部分。 Fab片段、单股可变区片段（scFv）和奈米抗体等先进形式的抗体片段相比传统单株抗体具有显着优势。蛋白质工程、展示技术和计算设计的进步推动了该领域的成长，这些进步提高了片段的稳定性、结合亲和性和可生产性。由于需要创新疗法来克服完整抗体的局限性，抗体片段正被探索为双特异性抗体、抗体药物复合体和CAR-T细胞构建体的基础组成部分。它们优异的特性不仅使其适用于影像和照护现场诊断，还能满足个人化医疗的需求。

推动全球抗体片段市场发展的因素

全球抗体片段市场的主要驱动因素之一是针对各种疾病（尤其是癌症）的标靶治疗需求不断增长。抗体片段以其对抗原的高特异性和亲和性而闻名，与传统抗体相比，它们在提高疗效和最大限度减少副作用方面正变得至关重要。这种向个人化医疗的转变，加上生物製药研发的进步以及人们对创新药物递送系统日益增长的兴趣，正在推动抗体片段的开发和应用。此外，抗体片段体积小，组织穿透性好，清除速度快，使其成为多种治疗应用的理想选择。

全球抗体片段市场限制因素

全球抗体片段市场的主要限制因素之一是研发和生产此类疗法的高成本。抗体片段的设计、生产和检验流程复杂，需要大量投资，这可能会阻碍小型公司进入市场，并限制创新。此外，严格的监管核准以及产品上市所需的漫长週期也是阻碍投资的挑战。因此，企业在努力推进抗体片段技术的同时，也要克服这些财务和监管方面的障碍，这可能会阻碍市场成长。

全球抗体片段市场趋势

全球抗体片段市场正经历显着成长，这主要得益于其应用领域的不断拓展，尤其是在肿瘤学和诊断领域。这些片段具有优异的肿瘤穿透性和快速从血液中清除的特性，因此在分子影像和标靶治疗的应用日益广泛。对基于片段的偶联物和双特异性抗体的关注，体现了业界对创新治疗方案的追求，旨在最大限度地提高治疗效果，同时最大限度地减少脱靶效应。这一趋势凸显了抗体片段在变革癌症治疗模式和提高诊断准确性方面的潜力，巩固了其作为不断发展的生物製药领域关键组成部分的地位。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境

全球抗体片段市场规模（按特异性和复合年增长率划分）（2026-2033 年）

• 单株抗体片段
• 多株抗体片段

全球抗体片段市场规模（以片段类型划分）及复合年增长率（2026-2033 年）

• Fab 碎片
• scFv（单链可变片段）
• 单域抗体（sdAb）
• 其他的

全球抗体片段市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 治疗药物
• 诊断
• 研究工具和工具包

全球抗体片段市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 肿瘤学
• 免疫学/自体免疫疾病
• 感染疾病
• 其他的

全球抗体片段市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Amgen Inc.
• Merck KGaA
• Genentech, Inc.
• Ablynx（Sanofi）
• Eli Lilly and Company
• Akeso, Inc.
• Taisho Pharmaceutical Co., Ltd.
• MacroGenics, Inc.
• Harpoon Therapeutics, Inc.
• Chengdu Huasun Technology Group Inc.
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Abcam plc
• Genscript Biotech Corporation

结论与建议

Global Antibody Fragments Market size was valued at USD 7.62 Billion in 2024 and is poised to grow from USD 8.06 Billion in 2025 to USD 12.65 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The antibody fragments market is emerging as a critical component within the biopharmaceutical industry, fueled by a rising demand for precise, adaptable, and efficient therapeutics and diagnostics. Advanced forms of antibody fragments, including Fab fragments, single-chain variable fragments (scFv), and nanobodies, offer distinct advantages over traditional monoclonal antibodies. Growth in this sector is bolstered by advancements in protein engineering, display technologies, and computational design, enhancing fragment stability, binding affinity, and manufacturability. With an increasing need for innovative therapeutic options addressing limitations of full antibodies, antibody fragments are being explored as foundational components for bispecific antibodies, antibody-drug conjugates, and CAR T-cell constructs. Their favorable characteristics make them suitable for imaging and point-of-care diagnostics, while aligning with the needs of personalized medicine approaches.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Fragments market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Fragments Market Segments Analysis

Global Antibody Fragments Market is segmented by Specificity, Fragment Type, Application, End Use and region. Based on Specificity, the market is segmented into Monoclonal Antibody Fragments and Polyclonal Antibody Fragments. Based on Fragment Type, the market is segmented into Fab Fragments, scFv (Single-Chain Variable Fragments), sdAb (Single-Domain Antibodies / Nanobodies) and Others. Based on Application, the market is segmented into Therapeutics, Diagnostics and Research Tools & Kits. Based on End Use, the market is segmented into Oncology, Immunology / Autoimmune Diseases, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Fragments Market

One of the key market drivers for the global antibody fragments market is the increasing demand for targeted therapies in the treatment of various diseases, particularly cancer. Antibody fragments, known for their high specificity and affinity to antigens, are becoming integral in enhancing therapeutic efficacy while minimizing side effects compared to traditional antibodies. This shift towards personalized medicine, coupled with advancements in biopharmaceutical research and the growing focus on innovative drug delivery systems, propels the development and adoption of antibody fragments. Additionally, their smaller size allows for better tissue penetration and faster clearance, making them highly attractive in a range of therapeutic applications.

Restraints in the Global Antibody Fragments Market

One significant market restraint for the global antibody fragments market is the high cost associated with the development and production of these therapeutic agents. The complex processes involved in engineering, manufacturing, and validating antibody fragments can lead to substantial investment requirements, which may restrict market entry for smaller companies and limit innovation. Additionally, stringent regulatory approvals and the lengthy timelines needed to bring these products to market present challenges that could deter investments. As a result, market growth may be hindered as companies navigate these financial and regulatory hurdles while striving to advance their antibody fragment technologies.

Market Trends of the Global Antibody Fragments Market

The Global Antibody Fragments market is experiencing a significant upsurge, particularly driven by their growing application in oncology and diagnostics. These fragments, characterized by their superior tumor penetration and rapid clearance from the bloodstream, are becoming increasingly favored for molecular imaging and targeted therapies. The focus on fragment-based conjugates and bispecific antibodies exemplifies the industry's pursuit of innovative treatment solutions that aim to minimize off-target effects while maximizing therapeutic efficacy. This trend highlights the potential of antibody fragments to revolutionize cancer treatment paradigms and enhance diagnostic accuracy, solidifying their role as critical components in the evolving landscape of biopharmaceuticals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Antibody Fragments Market Size by Specificity & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibody Fragments
• Polyclonal Antibody Fragments

Global Antibody Fragments Market Size by Fragment Type & CAGR (2026-2033)

• Market Overview
• Fab Fragments
• scFv (Single-Chain Variable Fragments)
• sdAb (Single-Domain Antibodies / Nanobodies)
• Others

Global Antibody Fragments Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutics
• Diagnostics
• Research Tools & Kits

Global Antibody Fragments Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Oncology
• Immunology / Autoimmune Diseases
• Infectious Diseases
• Others

Global Antibody Fragments Market Size & CAGR (2026-2033)

• North America (Specificity, Fragment Type, Application, End Use)
  • US
  • Canada
• Europe (Specificity, Fragment Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specificity, Fragment Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specificity, Fragment Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specificity, Fragment Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ablynx (Sanofi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harpoon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Huasun Technology Group Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations